Our Pricing

Mounjaro Havant: Your Complete Guide to Local Access and Delivery

Published: 3 October 2026

Residents searching for Mounjaro Havant now have convenient access to this prescription weight loss treatment through Cured Pharmacy's UK-registered online service. Our GPhC-registered pharmacy delivers genuine tirzepatide injections directly to homes across Havant, combining expert clinical assessment with discreet, next-day delivery from £124.99. Whether you're in Leigh Park, Bedhampton, or central Havant, accessing clinically proven weight management support has never been more straightforward.

How to Access Mounjaro Havant Through Cured Pharmacy

Obtaining Mounjaro Havant through our registered service involves a streamlined three-step process designed for convenience and clinical safety. First, complete our confidential online consultation form, which typically takes under three minutes and covers your medical history, current medications, and weight management goals. Our UK-registered prescribers review every assessment individually to ensure Mounjaro is clinically appropriate for your circumstances [1].

Once approved, your prescription is dispensed by our GPhC-registered pharmacy team under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073). We source only genuine, UK-licensed tirzepatide from authorised wholesalers, guaranteeing product authenticity and proper cold-chain storage. Your Mounjaro Havant order is then dispatched in completely discreet packaging via tracked courier, typically arriving within 24 hours to addresses throughout PO9 and surrounding postcodes.

All prescription medications require clinical assessment by a UK-registered prescriber before supply. Our transparent pricing model shows costs upfront—£124.99 for Mounjaro—with no hidden consultation fees. New patients can Save £20 using code Weightlossnew on their first order, making this evidence-based treatment accessible to more Havant residents seeking effective weight management solutions.

Mounjaro Havant Pricing and Dosage Options

Cured Pharmacy offers Mounjaro Havant at £124.99 representing competitive UK pricing for this dual GIP/GLP-1 receptor agonist. Each KwikPen contains four weekly doses, delivered in a graduated titration schedule that minimises gastrointestinal side effects while optimising weight loss outcomes. The standard dosing protocol begins at 2.5mg weekly for four weeks, increasing every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum maintenance dose of 15mg [2].

This gradual escalation reflects the SURPASS clinical trial methodology, where participants achieved average weight reductions of 15-22.5% of body weight over 72 weeks, depending on final dose strength [2]. Havant patients typically remain on each dose tier for one month before titrating upward, allowing the body to adapt to tirzepatide's appetite-suppressing and glucose-regulating effects. Our prescribers tailor dosing schedules to individual tolerance and response patterns.

Unlike some providers who bundle consultation fees into opaque pricing structures, our £124.99 cost covers the medication itself, with clinical assessment provided free of charge. This transparency helps Havant residents budget accurately for their weight management journey, which typically spans several months to achieve optimal results subject to prescriber guidance and individual response.

Understanding the Mounjaro Havant Titration Schedule

The graduated dosing approach used for Mounjaro Havant serves two critical clinical purposes: minimising common gastrointestinal side effects (nausea, diarrhoea, constipation) whilst allowing progressive weight loss over time. Starting at 2.5mg weekly gives your digestive system time to adapt to tirzepatide's slowed gastric emptying effect before increasing to therapeutic doses. Clinical trials demonstrated significantly better tolerability with this stepwise escalation compared to starting at higher doses [2].

Most Havant patients notice appetite reduction within the first week of treatment, though maximal weight loss typically occurs at maintenance doses of 10mg or 15mg weekly. Our prescribers monitor progress through follow-up consultations, adjusting the titration timeline if side effects require a slower escalation or if weight loss plateaus at a particular dose tier. This individualised approach optimises both safety and effectiveness throughout your treatment course.

Clinical Evidence Supporting Mounjaro Havant for Weight Loss

Residents considering Mounjaro Havant benefit from one of the most robust evidence bases in obesity pharmacotherapy. The SURPASS and SURMOUNT trial programmes enrolled over 10,000 participants, demonstrating tirzepatide's superior efficacy compared to placebo and active comparators including semaglutide [2][3]. In the pivotal SURMOUNT-1 trial, adults with obesity (BMI ≥30) or overweight with weight-related comorbidities (BMI ≥27) achieved average weight reductions of 15.0%, 19.5%, and 20.9% at the 5mg, 10mg, and 15mg doses respectively over 72 weeks [3].

These outcomes represent clinically meaningful weight loss associated with improvements in cardiovascular risk markers, glycaemic control, and quality of life measures. Approximately 89% of participants on the 15mg dose achieved at least 5% weight loss—the threshold considered clinically significant—whilst 57% achieved ≥20% reduction [3]. Such data underpins the MHRA's licensing of tirzepatide for chronic weight management in the UK, making it available to Havant residents through registered prescribers.

Beyond pure weight reduction, SURPASS trials documented improvements in HbA1c, blood pressure, lipid profiles, and inflammatory markers in participants with type 2 diabetes [2]. Though Mounjaro Havant is prescribed primarily for weight management through Cured Pharmacy, these metabolic benefits contribute to overall cardiometabolic health improvements. All outcomes remain subject to individual response, adherence to dosing schedules, and lifestyle modification including diet and physical activity.

Mounjaro Havant Delivery and Packaging Standards

Cured Pharmacy maintains pharmaceutical-grade cold-chain logistics to ensure your Mounjaro Havant arrives in optimal condition. Tirzepatide requires refrigerated storage between 2-8°C until first use, necessitating specialised packaging with temperature-controlled gel packs and insulated materials. Our dispatch process includes real-time temperature monitoring to verify product integrity throughout transit to Havant addresses.

All deliveries arrive in completely plain, discreet packaging with no external markings indicating pharmacy or medication contents. We use trusted courier partners offering tracked, signed-for delivery to ensure security and accountability. Most Havant orders placed before 2pm on working days are dispatched same-day for next-day delivery, though we recommend allowing 48 hours during peak periods or to more remote PO9 postcodes.

Upon arrival, store your Mounjaro Havant in the refrigerator immediately. Each KwikPen can be kept at room temperature (up to 30°C) for up to 21 days if needed, providing flexibility for travel or temporary storage situations. Our pharmacist-led customer service team remains available on (+44) 116 4646009 to address any storage, administration, or delivery queries specific to your Mounjaro Havant order.

What to Expect When Your Mounjaro Havant Order Arrives

Your Mounjaro Havant package includes the prescribed number of KwikPens (typically one box containing four weekly doses), patient information leaflet, and administration guide. First-time users should review the step-by-step injection instructions carefully, though the pre-filled pen design simplifies the process considerably. Injections are administered subcutaneously into the abdomen, thigh, or upper arm once weekly, on the same day each week regardless of meal timing.

If you have questions about injection technique or experience any unexpected side effects, contact our clinical team immediately. Common initial side effects include mild nausea, reduced appetite, and occasional digestive changes—these typically diminish as your body adapts to tirzepatide. Severe or persistent symptoms warrant prescriber review to assess whether dose adjustment or treatment modification is appropriate for your Mounjaro Havant regimen.

Who Can Use Mounjaro Havant: Eligibility Criteria

Mounjaro Havant is licensed for adults (18+ years) with a body mass index of ≥30 kg/m², or ≥27 kg/m² in the presence of at least one weight-related comorbidity such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease [1]. Our online consultation assesses your BMI, medical history, current medications, and previous weight management attempts to determine clinical suitability. Prescribers follow MHRA licensing criteria and NICE guidance when evaluating Mounjaro Havant requests.

Certain medical conditions preclude tirzepatide use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic ketoacidosis. Pregnancy and breastfeeding are absolute contraindications, and women of childbearing potential should use reliable contraception during treatment [1]. Our prescribers review these factors during clinical assessment to ensure patient safety.

Havant residents currently taking other GLP-1 receptor agonists (such as semaglutide, liraglutide, or dulaglutide) cannot use Mounjaro Havant concurrently due to overlapping mechanisms and increased side effect risk. If you're transitioning from another weight loss medication, our prescribers provide guidance on appropriate washout periods. All eligibility decisions rest with the assessing clinician, who may request additional information or suggest alternative treatments if Mounjaro is not suitable for your individual circumstances.

Mounjaro Havant: Safety, Side Effects, and Monitoring

The most common side effects reported with Mounjaro Havant mirror those observed in clinical trials: nausea (12-22% of participants), diarrhoea (13-16%), vomiting (6-10%), constipation (6-11%), and abdominal discomfort [2][3]. These gastrointestinal symptoms typically occur during dose escalation phases and diminish with continued use as tolerance develops. Eating smaller, more frequent meals and avoiding high-fat foods can help mitigate these effects during the initial weeks.

Rare but serious adverse events include pancreatitis, gallbladder disease, acute kidney injury (usually secondary to dehydration from vomiting/diarrhoea), and hypoglycaemia when used with insulin or sulfonylureas [1]. Patients should seek immediate medical attention for severe abdominal pain, persistent vomiting, signs of dehydration, or allergic reactions. Our prescribers provide detailed safety information during consultation and remain available for follow-up queries throughout your Mounjaro Havant treatment course.

Regular monitoring optimises safety and effectiveness. We recommend follow-up consultations every 12 weeks to assess weight loss progress, tolerability, and any emerging concerns. Havant patients who do not achieve at least 5% weight loss after 16 weeks on the maximum tolerated dose should discontinue treatment, as further benefit is unlikely [1]. Our clinical team supports these decisions, offering alternative weight management strategies when appropriate. Blood pressure and pulse monitoring at home can help track cardiovascular improvements as weight decreases.

Managing Side Effects with Mounjaro Havant

If you experience persistent nausea or gastrointestinal discomfort with Mounjaro Havant, several strategies can improve tolerability. Inject on an empty stomach or before bedtime to minimise daytime nausea. Stay well-hydrated, particularly if experiencing diarrhoea or vomiting. Ginger tea, small frequent meals, and avoiding trigger foods (spicy, fatty, or heavily processed items) often provide relief. If symptoms persist beyond the first month or worsen with dose increases, contact our prescribers to discuss slowing the titration schedule.

Never adjust your Mounjaro Havant dose independently—always consult the prescribing clinician before making changes. Some patients require extended time at lower doses (e.g., remaining on 5mg for eight weeks instead of four) to build tolerance before escalating. This individualised approach maintains treatment adherence whilst minimising dropout due to side effects, ultimately supporting better long-term weight management outcomes for Havant residents.

Scientific References

1. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. EMC. [accessed 3 October 2026]
2. Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 3 October 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 3 October 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 3 October 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 3 October 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 3 October 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.